Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03214679 · ClinicalTrials.gov registry record · NA
Accessible HCV Care Intervention for People Who Inject Illicit Drugs (PWID)
A NA study, sponsored by City University of New York, School of Public Health.
- Completed
- Registry status
- NA
- Development phase
- 167
- Enrollment target
NCT03214679: Completed NA study, sponsored by City University of New York, School of Public Health.
NCT03214679 is a NA study that has completed, run by City University of New York, School of Public Health. The registered enrollment target is 167 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (88% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03214679, a NA study, has completed, sponsored by City University of New York, School of Public Health.
- COMPLETED
- Registry status
- NA
- Development phase
- 167 participants
- Enrollment target
Study Summary
The proposed study will examine the feasibility, acceptability, safety, effectiveness, and cost of an Accessible Care intervention for engaging people who inject illicit drugs (PWID) in hepatitis C care. Accessible Care for PWID is low-threshold care provided in programs designed specifically for PWID where they can comfortably access care without fear of shame or stigma. Accessible Care will be provided by co-locating a hepatitis treatment provider, together with a Hepatitis C Care Coordinator (HCCC), on-site at a collaborating needle exchange program. The proposed study will compare the effectiveness of Accessible Care with Usual Care (referrals to existing services) in facilitating linkage, engagement, and retention of PWID in care for hepatitis C, addiction, and HIV prevention. The primary outcome is sustained virologic response, which constitutes virologic cure. Substance use and HIV and HCV risk behaviors are secondary outcomes.
Primary Outcome
SVR12 is a sustained virologic response to HCV treatment defined as HCV RNA below the limit of quantification 12 weeks post completion of HCV treatment
Interventions
- OTHER Usual Care
- OTHER Accessible Care
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 167 participants |
| Start Date | 2017-07-20 |
| Est. Completion | 2021-06-30 |
| Phase | NA |
What the finished NCT03214679 record still lists
NCT03214679 is an interventional study that assigns participants to a tested intervention. The registered 167 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (88% lower).
The record links to 0 conditions, and to 2 interventions - of which Usual Care is the first listed.
NCT03214679 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03214679 about?
NCT03214679 is a clinical study titled "Accessible HCV Care Intervention for People Who Inject Illicit Drugs (PWID)". The proposed study will examine the feasibility, acceptability, safety, effectiveness, and cost of an Accessible Care intervention for engaging people who inject illicit drugs (PWID) in hepatitis C care. Accessible Care for PWID is low-threshold care provided in programs designed specifically for PW...
What is the current status of trial NCT03214679?
This trial is currently completed. It is a NA study. The enrollment target is 167 participants. The study started on 2017-07-20. Estimated completion is 2021-06-30.
What interventions are being tested in trial NCT03214679?
The interventions under investigation include: Usual Care (OTHER), Accessible Care (OTHER).
Who is sponsoring clinical trial NCT03214679?
This trial is sponsored by City University of New York, School of Public Health, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03214679's enrollment target sits among peer trials
167 622nd of 2000 higher than 1,376 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04248283 · 167 participants · NA
Adjustable Continence Therapy (ACT) for the Treatment of Female SUI
- NCT04552509 · 167 participants · NA
TRUEBEAM Stereotactic Body Radiotherapy for Localized Prostate Cancer
- NCT05516277 · 167 participants · NA
Insomnia Treatment and Cardiometabolic Health in Older Adults With Posttraumatic Stress Disorder
- NCT02118922 · 168 participants
A Study to Test the Diagnostic Potential of Brillouin Microscopy for Corneal Ectasia
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI